Killing all the birds with one drug–is oral roflumilast a novel treatment option for psoriasis?

Keyphrases

• Novel Treatments 100%
• Psoriasis 100%
• Roflumilast 100%
• Comorbidity 40%
• Inflammatory Cytokines 20%
• Disease-associated 20%
• Mode of Action 20%
• Unmet Needs 20%
• Safety Profile 20%
• Therapeutic Challenges 20%
• Chronic Obstructive Pulmonary Disease 20%
• Psoriatic Skin 20%
• Chronic Inflammatory Skin Disease 20%
• Moderate-to-severe Psoriasis 20%
• Plaque Psoriasis 20%
• Phosphodiesterase 4 Inhibitor 20%
• Psoriasis Treatment 20%
• Refractory Disease 20%
• Skin Manifestations 20%
• Randomized Setting 20%
• Accessible Treatment 20%
• Phosphodiesterase 4 (PDE4) 20%

Medicine and Dentistry

• Psoriasis 100%
• Roflumilast 100%
• Oral 100%
• Treatment Option 100%
• Psoriasis Vulgaris 40%
• Comorbidity 40%
• Inflammatory Cytokine 20%
• Contraindication 20%
• Downregulation 20%
• Dermatitis 20%
• Chronic Obstructive Pulmonary Disease 20%
• Biological Product 20%
• Skin Manifestation 20%
• Phosphodiesterase IV Inhibitor 20%
• Phosphodiesterase IV 20%
• Diseases 20%

Pharmacology, Toxicology and Pharmaceutical Science

• Psoriasis 100%
• Roflumilast 100%
• Psoriasis Vulgaris 40%
• Comorbidity 40%
• Cytokine 20%
• Biological Product 20%
• Dermatitis 20%
• Skin Manifestation 20%
• Chronic Obstructive Lung Disease 20%
• Phosphodiesterase IV Inhibitor 20%
• Phosphodiesterase IV 20%
• Diseases 20%
• Mode of Action 20%